Chris Howerton
Stock Analyst at Jefferies
(2.68)
# 1,946
Out of 5,132 analysts
68
Total ratings
47.27%
Success rate
19.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNDA Vanda Pharmaceuticals | Maintains: Hold | $5 → $7.5 | $6.09 | +23.15% | 12 | Dec 31, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $79 → $125 | $70.07 | +78.39% | 3 | Dec 11, 2025 | |
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $6.87 | +16.45% | 5 | Jan 2, 2025 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $1.70 | +135.29% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $10 | $2.29 | +336.68% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $1.58 | +22,178.48% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $14.26 | +4,949.09% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $1.65 | -69.70% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $20.10 | -50.25% | 1 | Feb 8, 2023 | |
| APLS Apellis Pharmaceuticals | Downgrades: Hold | $70 → $40 | $21.70 | +84.33% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $36.01 | +69.40% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $181.21 | -50.33% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $0.37 | +5,311.26% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $22.97 | +187.33% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $5.68 | +287.32% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $0.93 | +2,153.22% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $0.65 | +3,265.97% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $22.03 | -4.68% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $80 → $580 | $8.47 | +6,747.70% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $2.36 | +2,442.37% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $39.97 | -59.97% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $81.49 | -66.87% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,200 | $1.39 | +86,230.94% | 1 | May 26, 2020 |
Vanda Pharmaceuticals
Dec 31, 2025
Maintains: Hold
Price Target: $5 → $7.5
Current: $6.09
Upside: +23.15%
Structure Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $79 → $125
Current: $70.07
Upside: +78.39%
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $6.87
Upside: +16.45%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $1.70
Upside: +135.29%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $10
Current: $2.29
Upside: +336.68%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $1.58
Upside: +22,178.48%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $14.26
Upside: +4,949.09%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $1.65
Upside: -69.70%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $20.10
Upside: -50.25%
Apellis Pharmaceuticals
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $21.70
Upside: +84.33%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $36.01
Upside: +69.40%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $181.21
Upside: -50.33%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $0.37
Upside: +5,311.26%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $22.97
Upside: +187.33%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $5.68
Upside: +287.32%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $0.93
Upside: +2,153.22%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $0.65
Upside: +3,265.97%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $22.03
Upside: -4.68%
Aug 11, 2020
Upgrades: Buy
Price Target: $80 → $580
Current: $8.47
Upside: +6,747.70%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $2.36
Upside: +2,442.37%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $39.97
Upside: -59.97%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $81.49
Upside: -66.87%
May 26, 2020
Initiates: Buy
Price Target: $1,200
Current: $1.39
Upside: +86,230.94%